Tesamorelin

Description

Tesamorelin (GHRH Analog)

Tesamorelin is a stabilized synthetic peptide analog of human Growth Hormone Releasing Hormone (GHRH). It differs from the natural peptide by the addition of a trans-3-hexenoic acid group at the N-terminal, which significantly increases its resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4).

In Canadian laboratory settings, Tesamorelin is primarily investigated for its metabolic impact. Unlike generic Growth Hormone secretagogues, Tesamorelin research centers on its high specificity for visceral fat reduction. It acts on the pituitary gland to stimulate the pulsatile release of endogenous growth hormone, subsequently increasing levels of Insulin-like Growth Factor 1 (IGF-1) to regulate body composition and lipid metabolism.

Technical Specifications

• Peptide Name: Tesamorelin
• Synonyms: TH-9507, GHRH (1-44) Analog
• CAS Number: 218949-48-5
• Molecular Formula: C221H366N72O67S
• Molar Mass: 5135.86 g/mol
• Purity: ≥99.0% (determined by HPLC)
• Appearance: White lyophilized powder
• Solubility: Soluble in sterile water or bacteriostatic water

Mechanism of Action (Research Context)
Tesamorelin research focuses on the “Pituitary-Growth Hormone Axis”:

• GHRH Receptor Agonism: Tesamorelin binds to GHRH receptors in the anterior pituitary gland, mimicking the action of natural GHRH to stimulate the synthesis and secretion of growth hormone (GH).
• Targeted Lipolysis: Studies investigate how the resulting GH release promotes the breakdown of triglycerides specifically in visceral fat cells (lipolysis), while sparing subcutaneous fat layers.
• IGF-1 Elevation: Research explores the systemic rise in IGF-1, which mediates many of the anabolic and metabolic effects of growth hormone, including improved muscle protein synthesis and glucose metabolism.
• Metabolic Flexibility: Investigations focus on Tesamorelin’s potential to improve insulin sensitivity and reduce inflammatory markers associated with visceral adiposity in experimental models.

Storage and Handling

• Lyophilized (Powder): Store at -20°C (-4°F) for long-term stability (up to 36 months). Tesamorelin is highly stable in its freeze-dried state; keep away from direct UV light and moisture.
• Reconstituted (Liquid): Once dissolved in a research solvent, the solution should be kept at 4°C (39°F) and utilized within 14–21 days. For maximum integrity, avoid vigorous agitation or repeat freeze-thaw cycles of the solution.
• Handling: Standard laboratory safety protocols apply. This product is for laboratory research use only.

Testing and Quality Control
At Flux Peptides, we provide the analytical transparency required for Canadian scientific publication. Every batch of Tesamorelin undergoes:

1. HPLC (High-Performance Liquid Chromatography): To confirm a purity profile of ≥99.0%.
2. MS (Mass Spectrometry): To verify the molecular identity of the N-terminally modified sequence.
3. Domestic Quality Check: Visual inspection and stability verification for the Canadian market.